# Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

> **NCT01405911** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 242 (actual)

## Conditions studied

- Glucose Intolerance

## Interventions

- **DRUG:** Placebo for Sitagliptin 25 mg
- **DRUG:** Placebo for Sitagliptin 50 mg
- **DRUG:** Sitagliptin 25 mg
- **DRUG:** Sitagliptin 50 mg

## Key facts

- **NCT ID:** NCT01405911
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-16
- **Primary completion:** 2012-04-09
- **Final completion:** 2012-04-09
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405911, "Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01405911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*